**Stage 1:**

**Case Presentation:**

A 55-year-old African American female presents to the outpatient clinic with a diffuse, pruritic rash that began 24 hours ago. The rash started 48 hours after receiving her third dose (first booster) of the mRNA COVID-19 vaccine (Moderna). She reports no previous adverse reactions to vaccines, including the prior two doses of the mRNA COVID-19 vaccine. However, she has a known allergy to penicillin, which previously caused an allergic reaction.

She describes the rash as itchy and notes that it has been progressively spreading. She denies any associated fever, chills, or other systemic symptoms.

**Past Medical History:**

- Chronic back pain for several months.

**Medications:**

- Gabapentin.

**Allergies:**

- Penicillin.

**Family History:**

- Non-contributory.

**Social History:**

- Denies tobacco, alcohol, and illicit drug use.

**Health-Related Behaviors:**

- Not applicable.

**Review of Systems:**

- Negative except as noted in the history of present illness.

**Vital Signs:**

- Temperature: 98.6°F (37°C)
- Heart Rate: 82 beats per minute
- Blood Pressure: 128/72 mmHg
- Respiratory Rate: 20 breaths per minute
- Oxygen Saturation: 97% on room air

**Physical Examination:**

- **General:** Alert and comfortable-appearing female, in no acute distress.
- **Skin:** Diffuse maculopapular, erythematous, non-blanching lesions predominantly on bilateral upper and lower extremities; few scattered lesions on the chest and back. No mucocutaneous involvement.
- **Head, Eyes, Ears, Nose, Throat (HEENT):** No lymphadenopathy; mucous membranes moist; no oral lesions.
- **Cardiovascular:** Normal heart sounds; no murmurs.
- **Respiratory:** Clear breath sounds bilaterally; no wheezes or crackles.
- **Abdomen:** Soft, non-tender; no hepatomegaly or splenomegaly.
- **Extremities:** Normal range of motion; no joint swelling or tenderness.
- **Neurological:** Alert and oriented; no focal deficits.
